Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06016634 · ClinicalTrials.gov registry record · Phase 2
Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
A Phase 2 study of Sickle Cell Disease and Avascular Necrosis, sponsored by University of California, Davis.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06016634 is a Phase 2 study of Sickle Cell Disease and Avascular Necrosis that is actively recruiting participants, run by University of California, Davis. The registered enrollment target is 30 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06016634, a Phase 2 study of Sickle Cell Disease and Avascular Necrosis, is actively recruiting participants, sponsored by University of California, Davis.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Conditions Studied
Interventions
- DRUG Alendronate Sodium
Study Locations (1)
California
- UC Davis Comprehensive Cancer Center - Sacramento
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-02-09 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06016634
The ClinicalTrials.gov registry entry for NCT06016634 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (90% lower). The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 1 intervention - of which Alendronate Sodium is the first listed.
NCT06016634 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06016634 about?
NCT06016634 is a clinical study titled "Alendronate for Osteonecrosis in Adults With Sickle Cell Disease". A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
What is the current status of trial NCT06016634?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-02-09. Estimated completion is 2027-12-31.
What conditions does trial NCT06016634 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Avascular Necrosis, Sickle Cell Anemia, Osteonecrosis, Ischemic Necrosis.
What interventions are being tested in trial NCT06016634?
The interventions under investigation include: Alendronate Sodium (DRUG).
Who is sponsoring clinical trial NCT06016634?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06016634 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.